RxDoctor Payments DataLook up a doctor →

Rakesh Prashad, MD

Interventional Cardiology · Ocala, FLNPI 1992800155

Payments from drug & device makers

$3,050,083in general payments, 2019–2025

Across 705 payments — averaging $4326.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.9M
  • Amgen$607K
  • Esperion Therapeutics, Inc.$189K
  • Kowa Research Institute, Inc.$125K
  • Boehringer Ingelheim International GmbH$62K
  • Bayer$39K
  • plus $93K from 45 others

What the payments were for

  • Travel & lodging$6,41139%
  • Food & beverage$9,89660%
  • Education$430%
  • Other$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,050,083 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$959,460
Medicare patients
1,317
Services billed
12,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban416$501,462
EntrestoSacubitril/Valsartan222$284,693
XareltoRivaroxaban137$173,527
FarxigaDapagliflozin Propanediol89$101,814
BrilintaTicagrelor27$22,429
Repatha SureclickEvolocumab23$19,690
Valsartan650$17,941
JardianceEmpagliflozin16$16,775
NexletolBempedoic Acid14$15,751
Prasugrel Hcl44$9,609
VascepaIcosapent Ethyl11$9,530
Atorvastatin Calcium685$6,788
Metoprolol Succinate366$5,583
Ezetimibe200$4,573
Amiodarone Hcl68$3,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$345$501,462416 claims
NovartisEntresto$1,934,834$284,693222 claims
Johnson & JohnsonXarelto$365$173,527137 claims
AstraZenecaFarxiga, Brilinta$165$124,243116 claims
Boehringer IngelheimJardiance$221$16,77516 claims
Esperion Therapeutics, Inc.Nexletol$189,080$15,75114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →